Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor
Article in Molecular and Cellular Biochemistry (March 2024)
The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.
HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4
Article in Journal of Endocrinological Investigation (February 2024)
Combined use of TLR4 and TLR7/8 agonists to improve the efficacy of immune checkpoint inhibitors in “hot” tumor treatment and the establishment of long-term immune protection
Preprint in Research Square (December 2023)